 for small molecules.){kind=link}
A newly established contract research organization, Peapod Bio, has announced the launch of services focused on assay development and high-throughput screening (HTS) for small molecules. The company employs both label-free and optical detection platforms, with a particular emphasis on a mass spectrometry–based approach that integrates polymeric enrichment arrays (PEAs) with matrix-assisted laser desorption/ionization (MALDI) instrumentation. This platform enables the rapid characterization of biochemical activity and binding interactions across diverse molecular targets.
According to founder and chief executive officer Zachary Gurard-Levin, Peapod Bio was created to address limitations often encountered in outsourcing early-phase drug discovery. In contrast to standardized workflows that may restrict experimental design, the company emphasizes a collaborative model in which assays are tailored to project-specific requirements.
We’re here to solve a persistent challenge when outsourcing early phase drug discovery. Rather than rely on legacy technologies and rigid, one-size-fits-all processes, we take a flexible and tailored approach, built on collaborative interactions and creative assay design to quickly generate decision-driving data.”
Dr. Zachary Gurard-Levin, CEO and founder of Peapod Bio
By positioning itself as an extension of client laboratories, Peapod Bio aims to streamline the generation of robust and reproducible datasets at an accelerated pace. The company anticipates that its integration of flexible assay design with mass spectrometry–driven detection will reduce risk in early discovery while facilitating the identification of high-quality therapeutic leads.